A closed Johnson & Johnson factory in the United States, which would have produced a defective volume of 15 million

LThe US pharmaceutical company FDA has demanded that Johnson & Johnson stop producing the vaccine at a plant that allegedly produced 15 million defective doses.

At the end of March, the pharmaceutical company AFP reported that it had found “substandard” quantities at a plant in Baltimore (Maryland), which is managed by Emergency Bio Solutions. Johnson & Johnson did not specify the size of the scales involved.

The New York Times later reported that the collection contained 15 million volumes.

Emergency bio-solutions in a file sent Monday to the Securities and Exchange Commission, the federal financial market regulator, on April 16 called for a halt to FDA Baltimore vaccine production.

“On April 16, 2021, at the request of the FDA, it was stated during the findings that Emergent should not begin production of any new material at its pavilion plant and that isolation and correction of products produced at the pavilion plant are pending (if there are any problems, author note). ”, The file declares.

The requested break in production is the latest problem of the vaccine in the United States, where regulators have suspended its use following reports of six cases of women developing blood clots with low platelet counts within two weeks. Johnson & Johnson vaccine is an injection.

The European Drug Administration (EMA) is set to rule on Tuesday on whether Johnson & Johnson’s vaccine is safe.